Merus stands out in biotech with its innovative ... Complex biologics also face difficulties in scaling up and maintaining consistency in manufacturing. Oncology competes fiercely.

Utrecht-based Merus is banking $40 million upfront from the deal, and getting a $20 million equity investment, but the total value could go north of $1.6 billion.

Legal & General Group Plc lessened its holdings in Merus (NASDAQ:MRUS – Free Report) by 1.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and ...

Merus N.V. announced that an abstract for petosemtamab combined with pembrolizumab as a first-line treatment for PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) has been ...

As per Goldman Sachs, Europe might face a big hit to economic growth as ... beating its benchmark by 150 percentage points (see more details here). Merus N.V. (NASDAQ:MRUS) is a clinical-stage ...